FDG PET/CT to predict EGFR mutation in lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial uses a special type of PET/CT scan (called FDG PET/CT) to see if it can predict whether your lung cancer has a specific gene change called EGFR mutation. If you have NSCLC and have already had an EGFR test, this study may help doctors find a less invasive way to check for that mutation in the future.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer (NSCLC).
- You must be 18 years or older.
- You must have had an EGFR mutation test (a test for a specific gene change in your cancer).
- Your PET/CT scan must have been done within one month before or after your EGFR test.
- You must not have started any cancer treatment before your EGFR test.
- Your blood sugar level must be above 200 mg/dL at the time of the PET/CT scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a newer PET/CT scan method to detect uncertain (indeterminate) lung nodules more accurately before biopsy or surgery. If you have a small lung nodule that doctors are still unsure about, this could help improve how nodules are found and assessed.
This study compares two types of scans (a special PET/CT called F-18 FDG and regular CT) to see how well they show the extent of non-small cell lung cancer before any treatment starts. It may help doctors choose the right approach for your care.
This study looks at gene-related information from a lung tumor sample and pairs it with special imaging to better understand non-small cell lung cancer. If you have a confirmed diagnosis and the right samples/tests, this may help researchers match patients to the most useful information for planning treatment.
This trial compares a two-step nuclear imaging scan (SPECT/CT) versus a PET/CT scan to see which works better for lung cancer. It may help guide doctors on the most useful imaging approach before you start lung-cancer treatment.
This trial is testing a new imaging probe that binds to EGFR mutations, which are common in some lung cancers. If you have lung cancer with a confirmed EGFR mutation, this scan may help doctors see your cancer more clearly.
This study uses a special PET-CT scan early in your treatment to see if immunotherapy (with or without chemotherapy) is working against your advanced lung cancer. The goal is to find out faster if the treatment is helping.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.